PRQR Stock Analysis: Buy, Sell, or Hold?
PRQR - ProQR Therapeutics N.V. Ordinary Shares
$2.43
0.09 (3.85%)
▲
5d:
+25.91%
30d:
+41.28%
90d:
+55.77%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 20, 2026
0d
Get Alerted When PRQR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: PRQR is 16.3% above its trading range ($2.09). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: PRQR is 16.3% above its trading range ($2.09). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: PRQR is currently trading at $2.43, which is considered extended relative to its 30-day fair value range of $1.69 to $2.09.
Technical Outlook: Technically, PRQR is in a uptrend. The price is approaching resistance at $2.46. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: PRQR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.22 (+238.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PRQR is in a uptrend. The price is approaching resistance at $2.46. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: PRQR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.22 (+238.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.69 -
$2.09
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+16.3% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.8%)
- BULLISH: Trading 238.4% below Wall St target ($8.22)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.69 -
$2.09
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.79
Resistance Level
$2.46
Current Trend
Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.14
Wall Street Target
$8.22
(+238.4%)
Revenue Growth (YoY)
120.4%
Profit Margin
-228.2%
Share & Embed Analysis
Last updated: August 24, 2026 5:56 PM ET
Data refreshes hourly during market hours. Next update: 6:56 PM
Data refreshes hourly during market hours. Next update: 6:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRQR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 39 SELL |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 55 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 46 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 45 HOLD |
